89
Participants
Start Date
December 1, 2017
Primary Completion Date
July 19, 2018
Study Completion Date
December 19, 2025
Pembrolizumab
Pembrolizumab administered intravenously every 3 weeks.
Epacadostat
Epacadostat administered orally twice daily.
Cetuximab
Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
Cisplatin
Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.
Carboplatin
Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.
5-Fluorouracil
5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
Allgemeines Krankenhaus der Stadt Wien, Vienna
Chris OBrien Lifehouse, Camperdown
Macquarie University Hospital, North Ryde
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc
Royal Brisbane & Women s Hospital, Herston
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet, Szolnok
Landeskrankenhaus Salzburg, Salzburg
National Taiwan University Hospital, Taipei
Pacific Cancer Medical Center, Anaheim
Huntsman Cancer Institute Univ of Utah, Salt Lake City
IRRCS Instituto Clinico Humanitas, Rozzano
Istituto Europeo di Oncologia, Milan
Trakya Universitesi Tip Fakultesi, Edirne
Hospital Ramon y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Infanta Cristina, Madrid
Northwest Georgia Oncology Centers PC, Douglasville
Chang Gung Medical Foundation. Linkou, Taoyuan District
Istanbul Universitesi Onkoloji Enstitusu, Istanbul
Medipol Hastanesi, Istanbul
Ege Universitesi Tip Fakultesi Hastanesi, Izmir
Baptist Health, Louisville
Hospital de Nuestra Senora de Valme, Seville
Inonu Universitesi Turgut Ozal Tip Merkezi, Malatya
Hospital Clinico Lozano Blesa, Zaragoza
St. Vincent Healthcare Cancer Ctr, Billings
U of Kansas Cancer Center, Westwood
National Cheng Kung University Hospital, Tainan City
Oklahoma Cancer Specialists and Research, Tulsa
University of Colorado Cancer Center, Aurora
New Mexico Cancer Care Alliance, Albuquerque
St. Joseph Heritage Healthcare, Santa Rosa
UC Davis Comprehensive Cancer Center, Sacramento
Providence Portland Med Center, Portland
Viginia Mason Med Ctr, Seattle
Yale Cancer Center, New Haven
Juravinski Cancer Center Hamilton Health Sciences, Hamilton
Princess Margaret Cancer Centre, Toronto
Jewish General Hospital, Montreal
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec, Québec
National Cancer Center Hospital East, Kashiwa
Kanazawa University Hospital, Kanazawa
Kanagawa Cancer Center, Yokohama
Miyagi Cancer Center, Natori-shi
Tohoku University Hospital, Sendai
Hyogo Cancer Center, Akashi
Kyushu University Hospital, Fukuoka
Hiroshima University Hospital, Hiroshima
Hokkaido University Hospital, Hokkaido
Kobe City Medical Center General Hospital, Kobe
Saitama Cancer Center, Saitama
Kindai University Hospital, Sayama
Shizuoka Cancer Center Hospital and Research Institute, Shizuoka
The Cancer Institute Hospital of JFCR, Tokyo
Mazowiecki Szpital Onkologiczny, Wieliszew
Przychodnia Lekarska Komed, Konin
Zachodniopomorskie Centrum Onkologii, Szczecin
Inst. Portugues de Oncologia de Coimbra Frencisco Gentil EPE, Coimbra
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisbon
Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria, Lisbon
Inst. Portugues de Oncologia de Porto Francisco Gentil EPE, Porto
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Hospital Germans Trias i Pujol. ICO de Badalona, Badalona
Hospital General Universitari Vall d Hebron, Barcelona
Adana Sehir Hastanesi, Adana
Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara
North Middlesex Hospital, London
University College London Hospitals (UCLH), London
The Royal Marsden Foundation Trust, London
The Royal Marsden Nhs Foundation Trust - Chelsea, London
Musgrove Park Hospital, Taunton
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Incyte Corporation
INDUSTRY